Suchergebnisse - "Wang, Chin-Chou"

PubPharm (8)

1

Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

enthalten in: Thoracic cancer | 2024

von Chiu, L. | Hsu, P. | Wang, C. | +6

2

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs

enthalten in: Thoracic cancer | 2023

von Chang, H. | Wang, C. | Tseng, C. | +7

3

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

enthalten in: Scientific reports | 2023

von Ju, J. | Huang, A. | Tung, P. | +10

4

Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors : A network meta-analysis of real-world evidence

enthalten in: Thoracic cancer | 2023

von Chang, H. | Huang, K. | Tseng, C. | +6

5

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I) : A Multicenter Observational Study in Taiwan

enthalten in: Targeted oncology | 2023

von Hsu, P. | Lee, S. | Chiu, L. | +9

6

Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation

enthalten in: International journal of cancer | 2022

von Huang, C. | Ju, J. | Chiu, T. | +9

7

Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib : A real-world study

enthalten in: Thoracic cancer | 2021

von Wang, C. | Lai, C. | Chang, Y. | +4

8

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

enthalten in: JTO clinical and research reports | 2021

von Park, K. | Tan, D. | Su, W. | +10

1
[1]